SCHEMBL2086534

SCHEMBL2086534

O=C(c1ccc(F)cc1)c1cn2cc(Cl)ccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
EGLN1 Q9GZT9 2/20 0.44
MAP3K5 Q99683 2/20 0.44
RAB9A P51151 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 3/20 0.42
TP53 P04637 1/20 0.41
F2 P00734 1/20 0.41
PLAU P00749 1/20 0.41
KLKB1 P03952 1/20 0.41
ELANE P08246 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
USP30 Q70CQ3 1/20 0.40
LTC4S Q16873 1/20 0.40
CYP2C19 P33261 1/20 0.40
CDK2 P24941 1/20 0.39
LTA4H P09960 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4213158 0.91 HRH4 (0.55) HRH4HRH3EGLN1MAP3K5RAB9A
SCHEMBL4250022 0.87 HRH4 (0.49) HRH4HRH3EGLN1MAP3K5RAB9A
SCHEMBL2086752 0.87 HRH4 (0.54) HRH4HRH3EGLN1MAP3K5RAB9A
SCHEMBL4243985 0.86 HRH4 (0.48) HRH4HRH3EGLN1MAP3K5RAB9A
SCHEMBL4211423 0.85 RAB9A (0.53) HRH4HRH3EGLN1RAB9AKDM4E
SCHEMBL2087864 0.84 HRH4 (0.46) HRH4HRH3EGLN1RAB9AKDM4E
SCHEMBL8933337 0.82 HPGD (0.55) HRH4HRH3EGLN1MAP3K5RAB9A
SCHEMBL4220034 0.81 HRH4 (0.48) HRH4HRH3EGLN1MAP3K5RAB9A
SCHEMBL8222627 0.81 NPC1 (0.52) HRH4HRH3EGLN1MAP3K5RAB9A
SCHEMBL2086460 0.79 PTGS1 (0.50) EGLN1MAP3K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040703-B1 DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2009-10-21 EP claimed
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US claimed
US-7902219-B2 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-08 US disclosed
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF NR4A2, NR4A3, NCOR1 HRH4 250/4885HRH3 241/4885EGLN1 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.